Latest News and Press Releases

Agios announces it will pursue U.S. accelerated approval for mitapivat in sickle cell disease

REHOVOT, Israel and HOBOKEN, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed...

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved...

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved...

PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progressionA Phase 2 proof-of-concept...

RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic...

PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative...

Lehi, UT, March 31, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, March 31, 2026 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to...

Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European...

Forte dynamique de développement au Venezuela Fleurieux-sur-l’Arbresle - France - le 31 mars 2026 à 8h. Après la signature d'un accord de distribution et le succès de la première chirurgie annoncés...

De nieuwe samenwerkingsstructuur levert aanzienlijk verbeterde financiële voorwaarden en flexibiliteit voor Galapagos op  Na deze transactie blijft de Vennootschap over het grootste deel van haar...

New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos  Following this transaction, the Company will continue to have a majority of its cash...

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, March 31, 2026 (GLOBE NEWSWIRE) --...

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between...

Pelvic Floor Strong exercise claims, Layer Syndrome framework, and Alex Miller's three-step pelvic floor method for women over 40 outlined.

Hume Health Hume Band claims evaluated — Metabolic Momentum, biological age tracking, AI longevity metrics, pricing, and what to verify in 2026.

Consumer update on fake NeuroSerge listings, product name variations, proprietary blend transparency, and ordering channel verification for 2026.

Okinawa Flat Belly Tonic 2026: lean belly tonic complaint patterns, before 10 AM fat-burning signal claims, adiponectin references, what to know.

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October...

2026 report covers MemoryON ingredient dosages, Bacopa and Phosphatidylserine research context, St. John's Wort safety, and pricing details.

Brain Savior explains its Brain Honey formula claims, Citicoline and Bacopa Monnieri research, and cognitive support positioning for 2026.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aquestive (AQST) To Contact Him Directly To Discuss Their Options If you purchased or...

Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued...

Carpinteria, CA, March 30, 2026 (GLOBE NEWSWIRE) -- This announcement is based on publicly available materials from ProHealth Longevity regarding its BPC-157 formulation, including how the product...

IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans...

RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data...

MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing of...

Name chosen for AVERSA Fentanyl commercial product

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Prog

Lexeo Earnings release

Chief Scientific Officer, Robert Allen, Ph.D., presented as part of the “Antibodies for Infectious Disease Workshop” at the World Vaccine Congress WashingtonPresentation titled “Developing mAb...

FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous...

Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical...

Sangamo Therapeutics reports recent business highlights and fourth quarter and full year 2025 financial results

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with...

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc." or the "Company") (NASDAQ: ATRA) of a class...

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP encourages investors who suffered losses in ImmunityBio, Inc. (NASDAQ: IBRX) to contact the firm. WHO IS AFFECTED: Those who...

NEW YORK, March 30, 2026, March 30, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP encourages investors who suffered losses in REGENXBIO, Inc. (NASDAQ: RGNX) to contact the firm. Those who...

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) of a class action securities lawsuit. CLASS...

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inovio Pharmaceuticals, Inc. ("Inovio Pharmaceuticals, Inc." or the "Company") (NASDAQ: INO) of a class...

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated" or the "Company") (NASDAQ: CORT)...

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Institutional investors holding positions in Soleno Therapeutics, Inc. (NASDAQ: SLNO) during the period March 26, 2025 through November 4, 2025 may wish...

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Institutional investors holding positions in Aquestive Therapeutics, Inc. (NASDAQ: AQST) during the period from June 16, 2025 through January 8, 2026 may...

BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its...

- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001)  - Acoramidis mitigated the rise in NT-proBNP...

AquaBurn 2026 brown fat thermogenic formula: ingredient research context, product disclosures, and supplement vs. prescription distinctions.

LOS ANGELES, March 30, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed...

LOS ANGELES, March 30, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...

New class action for Atara (ATRA) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 5/22/2026.